Rui Li, M.D. brings over 15 year years of clinical research experience to Kezar as a Vice President, Clinical Development, Oncology. Dr. Li has worked in small to large size of pharmaceutical companies including Roche, Janssen, Dainippon Sumitomo, Allergan, Lundbeck, and Luye. She had increasing responsibilities including drug safety and clinical development. She led a number of global teams as Head of Global Clinical Development, Clinical Leader, Medical Monitor, Medical Safety Physician, supported more than 20 IND and NDA submissions in multiple therapeutical areas, including oncology and was responsible for all development activities including clinical and non-clinical science, clinical operations, drug safety, regulatory, and medical affairs. Most relevant to Kezar, She has worked on programs of targeting gene mutations, anti-PD-1 monoclonal antibodies, and CAR-T cell therapy in solid tumors. Prior to joining industry, she spent about 5 years in leadership roles within DNA sequencing and oligonucleotide synthesis facility of cancer center at Albert Einstein College of Medicine of Yeshiva University. Dr. Li is a physician trained in OB/GYN and GYN oncology having completed her studies at the Medical School affiliated with Shanghai Jiao Tong University and Bengbu Medical College, and then practiced at Shanghai Renji Hospital. In addition, Dr. Li was a PhD candidate in the School of Pharmacy at the State University of New York at Buffalo.